| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
113 |
| issn |
1718-7729 |
| issueIdentifier |
2 |
| pageRange |
112-113 |
| publicationName |
Current oncology (Toronto, Ont.) |
| startingPage |
112 |
| bibliographicCitation |
Laing K. Managing the Toxicities of the FEC-100 Followed by Docetaxel Regimen: The Price of Success. Current Oncology. 2008 Apr 01;15(2):112–3. doi: 10.3747/co.v15i2.263. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_556a20fb90a24bf1162dd4e5d7d83e82 |
| date |
2008-04-01^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.3747/co.v15i2.263
https://pubmed.ncbi.nlm.nih.gov/18454184
https://pubmed.ncbi.nlm.nih.gov/PMC2365481 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33334
https://portal.issn.org/resource/ISSN/1718-7729 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Managing the Toxicities of the FEC-100 Followed by Docetaxel Regimen: The Price of Success |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 |